This is an old revision of this page, as edited by Ayrton Prost (talk | contribs) at 20:15, 29 August 2008 (AfD: Nominated for deletion; see Misplaced Pages:Articles for deletion/Apricitabine). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:15, 29 August 2008 by Ayrton Prost (talk | contribs) (AfD: Nominated for deletion; see Misplaced Pages:Articles for deletion/Apricitabine)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)| An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it.Feel free to improve the article, but do not remove this notice before the discussion is closed. For more information, see the guide to deletion. Find sources: "Apricitabine" – news · newspapers · books · scholar · JSTOR%5B%5BWikipedia%3AArticles+for+deletion%2FApricitabine%5D%5DAFD |
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C8H11N3O3S |
| Molar mass | 229.256 g/mol g·mol |
Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI).
It was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold the Shire Pharmaceuticals (where the drug was called SPD754). Shire then sold the rights to develop the drug to Avexa, an Australian pharmaceutical company.
References
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |